Koralia Paschalaki

Koralia Paschalaki

Auto-generated profile, based on publicly available information

Koralia Paschalaki

National Heart and Lung Institute, Imperial College London, London, United Kingdom

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2011 in Blood
Verified
Journal Article
Open access
PDF file
RSRichard D. Starke
Richard D. Starke
FFFrancesco Ferraro
Francesco Ferraro
KPKoralia E. Paschalaki
Koralia E. Paschalaki
NDNicola H. Dryden
Nicola H. Dryden
TMThomas A. J. McKinnon
Thomas A. J. McKinnon
ARAnna M. Randi
Anna M. Randi
The regulation of blood vessel formation is of fundamental importance to many physiological processes, and angiogenesis is a major area for novel therapeutic approaches to diseases from ischemia to cancer. A poorly understood clinical manifestation of pathological angiogenesis is angiodysplasia, vascular malformations that cause severe gastrointestinal bleeding. Angiodysplasia can be associated with von Willebrand disease (VWD), the most common bleeding disorder in man. VWD is caused by a defect or deficiency in von Willebrand factor (VWF), a glycoprotein essential for normal hemostasis that is involved in inflammation. We hypothesized that VWF regulates angiogenesis. Inhibition of VWF expression by short interfering RNA (siRNA) in endothelial cells (ECs) caused increased in vitro angiogenesis and increased vascular endothelial growth factor (VEGF) receptor-2 (VEGFR-2)–dependent proliferation and migration, coupled to decreased integrin αvβ3 levels and increased angiopoietin (Ang)–2 release. ECs expanded from blood-derived endothelial progenitor cells of VWD patients confirmed these results. Finally, 2 different approaches, in situ and in vivo, showed increased vascularization in VWF-deficient mice. We therefore identify a new function of VWF in ECs, which confirms VWF as a protein with multiple vascular roles and defines a novel link between hemostasis and angiogenesis. These results may have important consequences for the management of VWD, with potential therapeutic implications for vascular diseases.

29 July 2013 in Stem Cells
Verified
Journal Article
Open access
PDF file
KPKoralia E. Paschalaki
Koralia E. Paschalaki
RSRichard D. Starke
Richard D. Starke
YHYanhua Hu
Yanhua Hu
NMNicolas Mercado
Nicolas Mercado
AMAndriana Margariti
Andriana Margariti
PBPeter Barnes
Peter Barnes
Cardiovascular disease (CVD) is a major cause of death in smokers, particularly in those with chronic obstructive pulmonary disease (COPD). Circulating endothelial progenitor cells (EPC) are required for endothelial homeostasis, and their dysfunction contributes to CVD. To investigate EPC dysfunction in smokers, we isolated and expanded blood outgrowth endothelial cells (BOEC) from peripheral blood samples from healthy nonsmokers, healthy smokers, and COPD patients. BOEC from smokers and COPD patients showed increased DNA double‐strand breaks and senescence compared to nonsmokers. Senescence negatively correlated with the expression and activity of sirtuin‐1 (SIRT1), a protein deacetylase that protects against DNA damage and cellular senescence. Inhibition of DNA damage response by silencing of ataxia telangiectasia mutated (ATM) kinase resulted in upregulation of SIRT1 expression and decreased senescence. Treatment of BOEC from COPD patients with the SIRT1 activator resveratrol or an ATM inhibitor (KU‐55933) also rescued the senescent phenotype. Using an in vivo mouse model of angiogenesis, we demonstrated that senescent BOEC from COPD patients are dysfunctional, displaying impaired angiogenic ability and increased apoptosis compared to cells from healthy nonsmokers. Therefore, this study identifies epigenetic regulation of DNA damage and senescence as pathogenetic mechanisms linked to endothelial progenitors' dysfunction in smokers and COPD patients. These defects may contribute to vascular disease and cardiovascular events in smokers and could therefore constitute therapeutic targets for intervention. Stem Cells 2013;31:2813–2826

1 April 2011 in Chest
Verified
Journal Article
Closed access
PDF file
FDFotios Drakopanagiotakis
Fotios Drakopanagiotakis
KPKoralia Paschalaki
Koralia Paschalaki
MAMuhanned Abu-Hijleh
Muhanned Abu-Hijleh
BABassam Aswad
Bassam Aswad
NKNapoleon Karagianidis
Napoleon Karagianidis
VPVlasis Polychronopoulos
Vlasis Polychronopoulos

23 October 2018 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
KPKoralia E. Paschalaki
Koralia E. Paschalaki
ARAnna M. Randi
Anna M. Randi
The term “Endothelial progenitor cell” (EPC) has been used to describe multiple cell populations that express endothelial surface makers and promote vascularisation. However, the only population that has all the characteristics of a real “EPC” is the Endothelial Colony Forming Cells (ECFC). ECFC possess clonal proliferative potential, display endothelial and not myeloid cell surface markers, and exhibit pronounced postnatal vascularisation ability in vivo. ECFC have been used to investigate endothelial molecular dysfunction in several diseases, as they give access to endothelial cells from patients in a non-invasive way. ECFC also represent a promising tool for revascularization of damaged tissue. Here we review the translational applications of ECFC research. We discuss studies which have used ECFC to investigate molecular endothelial abnormalities in several diseases and review the evidence supporting the use of ECFC for autologous cell therapy, gene therapy and tissue regeneration. Finally, we discuss ways to improve the therapeutic efficacy of ECFC in clinical applications, as well as the challenges that must be overcome to use ECFC in clinical trials for regenerative approaches.

4 April 2013 in Blood
Verified
Journal Article
Open access
PDF file
RSRichard D. Starke
Richard D. Starke
KPKoralia E. Paschalaki
Koralia E. Paschalaki
CDClare Dyer
Clare Dyer
KHKimberly J. Harrison-Lavoie
Kimberly J. Harrison-Lavoie
JCJacqueline A. Cutler
Jacqueline A. Cutler
ARAnna M. Randi
Anna M. Randi
Key Points: BOECs from VWD patients provide novel insight into the cellular mechanisms of the disease.

9 July 2013 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
Andras BikovAndras Bikov
Andras Bikov
KPKoralia Paschalaki
Koralia Paschalaki
RLRon Logan-Sinclair
Ron Logan-Sinclair
Ildikó HorváthIldikó Horváth
Ildikó Horváth
SPSergei Kharitonov Md Phd
Sergei Kharitonov Md Phd
PPPaolo Paredi
Paolo Paredi
Background: Exhaled breath volatile organic compound (VOC) analysis for airway disease monitoring is promising. However, contrary to nitric oxide the method for exhaled breath collection has not yet been standardized and the effects of expiratory flow and breath-hold have not been sufficiently studied. These manoeuvres may also reveal the origin of exhaled compounds. Methods: 15 healthy volunteers (34 ± 7 years) participated in the study. Subjects inhaled through their nose and exhaled immediately at two different flows (5 L/min and 10 L/min) into methylated polyethylene bags. In addition, the effect of a 20 s breath-hold following inhalation to total lung capacity was studied. The samples were analyzed for ethanol and acetone levels immediately using proton-transfer-reaction mass-spectrometer (PTR-MS, Logan Research, UK). Results: Ethanol levels were negatively affected by expiratory flow rate (232.70 ± 33.50 ppb vs. 202.30 ± 27.28 ppb at 5 L/min and 10 L/min, respectively, p < 0.05), but remained unchanged following the breath hold (242.50 ± 34.53 vs. 237.90 ± 35.86 ppb, without and with breath hold, respectively, p = 0.11). On the contrary, acetone levels were increased following breath hold (1.50 ± 0.18 ppm) compared to the baseline levels (1.38 ± 0.15 ppm), but were not affected by expiratory flow (1.40 ± 0.14 ppm vs. 1.49 ± 0.14 ppm, 5 L/min vs. 10 L/min, respectively, p = 0.14). The diet had no significant effects on the gasses levels which showed good inter and intra session reproducibility. Conclusions: Exhalation parameters such as expiratory flow and breath-hold may affect VOC levels significantly; therefore standardisation of exhaled VOC measurements is mandatory. Our preliminary results suggest a different origin in the respiratory tract for these two gasses.